Impact of early vs. late time-restricted eating on lipid metabolism in women with overweight or obesity

Kristof Szekely[1,2], Mathias J. Gerl[3], Beeke Peters[1,4], Julia Schwarz[1,5], Bettina Schuppelius[1,2,4], Markus Damm[3], Jorge R. Soliz-Rueda[1,4], Ratika Sehgal[4,6], Michail Lazaratos[4,6], Christian Klose[3], Kai Simons[3], Andreas F. H. Pfeiffer[2,4], Annette Schürmann[4,6], Achim Kramer[7], Andreas Michalsen[8,9], Olga Pivovarova-Ramich[1,2,4,5]∗

[1]*Department of Molecular Metabolism and Precision Nutrition, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany;*

[2]*Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism, 10117 Berlin, Germany;*

[3]*Lipotype GmbH, 01307 Dresden, Germany;*

[4]*German Center for Diabetes Research (DZD), 85764 München-Neuherberg, Germany;*

[5]*Institute of Agricultural and Nutritional Sciences, Martin Luther University Halle-Wittenberg, 06120 Halle, Germany;*

[6]*Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany;*

[7]*Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and Humboldt-Universität zu Berlin, Laboratory of Chronobiology, Institute for Medical Immunology, 10117 Berlin, Germany;*

[8]*Department of Internal and Integrative Medicine, Immanuel Hospital Berlin, Berlin, Germany;*

[9]*Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, and Humboldt-Universität zu Berlin, Institute of Social Medicine, Epidemiology and Health Economics, 10117 Berlin, Germany*

Short title: Early vs. late time-restricted eating and plasma lipidome

*Correspondence: Olga Pivovarova-Ramich, German Institute of Human Nutrition Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany, E-mail: olga.ramich@dife.de

Summary

Time-restricted eating (TRE) is a promising strategy to prevent obesity and type 2 diabetes, but its effects on the lipid metabolism are controversial. This crossover study examined 31 overweight or obese women who followed a two-week early TRE (eTRE) and a two-week late TRE (lTRE). Plasma lipid profiles were analyzed using shotgun lipidomics before and after each intervention. eTRE affected 103 lipid species, reducing ceramides and phosphatidylcholines, and altered the activity indices of desaturases D5D, D6D, and D9D, as well as elongase ELOVL6. lTRE altered D5D index but caused no substantial changes in lipid species and classes. Combined analysis of plasma lipidome and subcutaneous adipose tissue biopsies revealed alterations in the glycerophospholipid pathway and the expression of phospholipase enzymes PLB1, PLA2G6, and PLAG4B by the TRE timing. These results suggest that the eating timing during TRE is crucial for remodeling lipid metabolism, warranting consideration in future dietary research and recommendations.

Key words: plasma lipidome, time-restricted eating, meal timing, lipid metabolism, adipose tissue

Introduction

In recent years, intermittent fasting (IF) has become increasingly popular within the scientific community and beyond. One type of IF is time-restricted eating (TRE), in which food intake is limited to 6 to 10 hours a day. The reason for the popularity of this approach, in addition to its numerous beneficial effects, is an easy implementation [1]. In the last years, the effects of TRE have been intensively studied, and so far improvements have been observed for body weight [2-17], body fat [3, 4, 7, 8, 10, 12, 13, 15, 16], waist circumference [9, 10, 15, 18], inflammatory markers [8, 16], oxidative stress [7, 19], blood pressure [6, 10, 12, 19], blood glucose parameters [3, 7, 8, 11, 14, 19, 20], sleep, and overall quality of life [2, 9]. Therefore, TRE is a promising prevention and treatment approach improving the metabolic state in obesity and type 2 diabetes. In these diseases, dysfunctions of carbohydrate and lipid metabolism are closely interrelated. In particular, dyslipidemia was described in type 2 diabetes mellitus [21]. However, the effects of TRE on the lipid metabolism are still poorly investigated and the data are partly controversial.

Several studies, which studied effects of TRE on the lipid metabolism, found an improvement in triglycerides [3, 4, 8, 14, 22] and cholesterol levels [10, 22]. Nevertheless, these results vary depending on the study design and study cohort, with other studies showing no change or even a worsening of lipid metabolism [5-7, 9-13, 19, 20, 23].

In addition to these parameters used in everyday clinical practice, the development of novel research techniques such as high throughput shotgun lipidomics offers a significantly more accurate approach to assessing a broader range of plasma lipids [24]. Using this method, a reduction in sphingosines and different sphingomyelins was observed after some IF interventions, e.g. the Ramadan fast [25]. In our previous research, the shotgun lipidomic analysis allowed to reveal and characterize in detail, daytime-dependent changes in postprandial lipid metabolism [26], confirming that the timing of meal intake modulates dietary-induced metabolic responses. However, so far, no lipidomic study has directly compared effects of early and late eating windows in terms of the TRE. To fill this gap, we assessed the impact of both early (eTRE) and late (lTRE) TRE on the plasma lipid pattern in a carefully controlled crossover study conducted in overweight or obese women [27]. To consider a contribution of adipose tissue in lipid homeostasis upon TRE, we combined the plasma lipidome with gene expression profiling in the subcutaneous adipose tissue (SAT).

Results

Study population and adherence to the dietary interventions

31 female subjects with overweight or obesity (age: 62 (53-65) years; BMI: 30.5 ± 2.9 kg/m^2), 13 with impaired fasting glucose /impaired glucose tolerance (IFG/IGT) and 18 with normal glucose tolerance (NGT), completed this study. Baseline characteristics of study participants are shown in **Table 1**. Details of this trial are described in **Figure 1A**, **Table S1**, the **STAR Methods** section, and Peters et al [27]. In brief, after a two-to-four-week baseline period, participants followed a two-week eTRE and a two-week lTRE intervention in a crossover design. They showed a high adherence to the 8-hour eating window in both TRE interventions. During the baseline phase, the participants' median eating window was 11:48 (10:50 - 13:15) h per day, which decreased to 7:09 (6:57 - 7:21) h during the eTRE intervention, and to 6:57 (6:39 - 7:16) h during the lTRE intervention. The subjects maintained a high timely compliance of 96.5 % (6.3 %) in eTRE and 97.7 % (6.1 %) in lTRE. A minor decrease in daily energy intake was observed during the eTRE intervention (-167 kcal; 95% CI, -249 to -86 kcal; P < 0.001), but not during lTRE. There was no difference in macronutrient composition and physical activity between and within the two TRE interventions (**Table S2).**

Detected Plasma Lipids

Lipid profiles could be determined in 30 subjects for the eTRE intervention and in 31 subjects for the lTRE intervention. Lipidomics analysis of plasma samples yielded on average 10534 ± 2768 pmol (n = 154) of lipids per µL of sample. Lipid species from 14 lipid classes (cholesterol (Chol), cholesterol esters (CE), triacylglycerols (TAG), diacylglycerols (DAG), phosphatidylcholines (PCs), phosphatidylcholine ethers (PC O-), phosphatidylethanolamines (PE), phosphatidylethanolamine ethers (PE O-), phosphatidylinositols (PI), lysophosphatidylcholines (LPC), lysophosphatidylcholine ethers (LPC O-), lysophosphatidylethanolamines (LPE), sphingomyelins (SM), and ceramides (CER) were identified and quantified (**Table S3)**. Lipid species present in less than 70% of all samples were excluded, resulting in a total of 300 lipid species for further analysis. This procedure accounted for for 99% (98.9 ± 0.6 (n = 154)) of the total lipid content.

Plasma lipid patterns were analyzed for changes of (i) lipid species, (ii) lipid classes, (iii) fatty acids; (iv) indices of desaturase and elongase activities; (v) double bonds; (vi) total carbon lengths – within the eTRE and lTRE and compared effects of both interventions.

Effects of eTRE on the plasma lipidome

The eTRE caused a decrease in 103 lipid species after vs. before the intervention, as shown after the correction for multiple testing (**Figure 1B, Table S4**). Analysis of lipid classes revealed a reduction of ceramides (P = 0.043) and phosphatidylcholines (P = 0.043) within the eTRE intervention (**Figure 2A, Table S5**).

Based on the level of specific fatty acids (FA) within complex lipids (**Table S6**), we further quantified indices of desaturation and elongation as surrogate markers of corresponding enzyme activity (**Table S7**). Within the eTRE, the elongation index ELOVL6 (calculated as FA 18:0 to FA 16:0 ratio[28]) was decreased (P < 0.001), whereas the ELOVL5 index was not altered (calculated as FA 20:3 to FA 18:3 ratio[28]) (**Figure 2B, Table S8**). In agreement with this, the level of stearic acid 18:0 decreased within the eTRE intervention (P = 0.010) (**Table S6**). The total carbon chain length was altered in 22 lipid class subgroups across 10 lipid classes, with each subgroup containing all lipid species from the same lipid class with identical carbon chain length (**Table S9**).

The desaturation indices delta-5 desaturase (D5D/FADS1, calculated as FA 20:4 to FA 20:3 ratio [28-30], P = 0.002) and delta-9 desaturase (D9D/SCD1) for C18 (calculated as FA 18:1 to FA 18:0 ratio [28, 31, 32],P = 0.007) increased, while the indices of delta-6 desaturase (D6D/FADS2, calculated as FA 18:3 to FA 18:2 ratio [28], P = 0.035) decreased within the eTRE (**Figure 2B, Table S8**). In agreement with this, the level of alpha-linolenic acid 18:3, used for the calculation of the D6D index), decreased following the eTRE intervention (p = 0.026) (**Table S8**). In general, the number of double bonds showed alterations in 39 lipid subgroups across 12 lipid classes, with each subgroup containing all lipid species from the same lipid class with identical number of double bonds (**Table S10**).

Effects of lTRE on the plasma lipidome

The lTRE induced no alterations of lipid profiles for lipid species and classes after vs. before the intervention, which remained significant after the correction for multiple testing. No lTRE-induced changes in FA levels were found.

FA-derived elongation indices were not altered within lTRE. Total carbon chain length was altered in three lipid subgroups across two lipid classes (**Table S11**)**.** The D5D/FADS1 index was increased within the lTRE (P < 0.001) (**Figure 2B, Table S8**). The number of double bonds showed alterations in six lipid subgroups across five lipid classes (**Table S12**)**.** Taken together, lTRE induced less pronounced plasma lipidome compared to eTRE.

Effects of eTRE and lTRE on key lipid enzymes in adipose tissue

We further hypothesized that the expression of key lipid metabolism genes in adipose tissue can be affected by eTRE and lTRE and is consistent with the alterations of ceramides and phosphatidylcholines observed in plasma. To investigate this, we assessed the expression of key genes involved in phosphatidylcholine biosynthesis (*CHPT1, CETP1*) and ceramide biosynthesis (*SPTLC2, CERS6*) in SAT samples collected after the eTRE and lTRE using qPCR (**Table S13**). No difference of the expression of these genes was found between both interventions (**Figure 2C**).

In addition to these genes, we have investigated the expression of genes responsible for key lipid metabolism processes in SAT, i.e. 1) desaturases (*FADS1* also known as *D5D, FADS2* also known as *D6D,* and *SCD1* also known as *D9D*), 2) elongases (*ELOVL5* and *ELOVL6*), and 3) genes of fatty acid synthesis (*FASN, ACC1,* and *ACSL1*). Most of the selected genes (as well as ceramide and phosphatidylcholine biosynthesis genes mentioned above) demonstrated circadian rhythms in previous human research [33-38]. We therefore hypothesized that the 24-hour rhythms of these lipid species can be influenced by the timing of the eating window during eTRE and lTRE interventions. The mRNA expression after the lTRE intervention was higher than after eTRE for the desaturases *FADS1* (P = 0.008) and *SCD1* (P = 0.008) as well as for the elongase *ELOVL6* (P = 0.013) (**Figure 2D**). For all other genes examined, no difference between eTRE and lTRE expression levels were found.

Lipid pathway enrichment combined with adipose tissue analysis

To elucidate further lipid metabolism pathways which underwent remodeling by the TRE interventions, we conducted a lipid pathway enrichment analysis of the altered plasma lipidome as described in **STAR Methods**. This analysis identified that the glycerophospholipid pathway was significantly affected by eTRE (**Table S14**). Based on this, we further decided to look for the changes in expression profile of enzymes/genes (based on RNA sequencing) involved in glycerophospholipid pathway (**Figure 3A**I [Gaugel J., Haacke N., Lazaratos M., submitted, https://metakegg.apps.dzd-ev.org, https://github.com/dife-bioinformatics/metaKEGG] to visualize observed glycerophospholipid pathway changes on both lipidomic and the transcriptomic layers. Genes found in the RNAseq dataset were directly mapped on the pathway and colored according to their $\log_2$(FC) (**Figure S1**). This allowed to identify three genes, involved in the glycerophospholipid pathway and coding phospholipase enzymes, which were regulated differently after eTRE and lTRE interventions (**Figure 3B-C**). *PLB1* and *PLA2G6* were downregulated, while *PLAG4B* were upregulated after the eTRE intervention compared to the lTRE.

Discussion

In this work, we investigated for the first time the effect of early and late TRE regimens on lipid metabolism and compared them using high throughput lipidomic analysis. Importantly, this carefully controlled study was conducted in a nearly isocaloric setting accompanied by the unchanged food composition and physical activity to ensure that plasma lipid changes were caused by the shortening and/or timing of the eating window itself independent of the calorie deficit, changes of the food composition, or physical activity.

The main finding of this study is that TRE-induced changes of plasma lipidome depend on the timing of the eating window. In addition to the altered elongase and desaturase indices, we found that the expression of key lipid metabolism enzymes in adipose tissue also differ between the two interventions depending on meal timing, highlighting the possible contribution of adipose tissue to the TRE-induced lipid changes in the circulation.

Importantly, in our trial, eTRE had more pronounced effects on the plasma lipidome compared to lTRE. Indeed, eTRE intervention caused a decrease in 103 of the analyzed lipid species, whereas lTRE showed no effect on lipid species. Similar differences were also observed on the level of lipid classes and enzyme activity indices. While the eTRE caused a

reduction of ceramides and phosphatidylcholines, as well as an alteration of several elongation and desaturation indices, the lTRE caused a change in the D5D index only. Accordingly, eTRE induced more changes in the number of total double bonds and total carbon chain length per class than lTRE.

The marked differences in the impact of eTRE and lTRE on the plasma lipidome agree with previous TRE research results. According to the current state of knowledge, eating in the beginning of the day in terms of the TRE intervention appears to maximize metabolic benefits. Many eTRE studies have shown that limiting food intake to the morning enhances insulin sensitivity, beta-cell responsiveness, blood pressure, inflammation, and oxidative stress [11, 19, 20, 39]. Conversely, lTRE, where food intake is restricted to the late afternoon or evening (after 4 pm), either had no effect or worsened blood glucose, beta-cell responsiveness, and lipid levels [5, 7, 8, 13, 40]. Importantly, only one study to date has directly compared eTRE and lTRE in a cross-over design by Hutchison et al. [14]. This study found that postprandial glucose decreased with both diets, but mean fasting glucose, as measured by continuous glucose monitoring (CGM), improved only with eTRE, while fasting triglycerides decreased with both diets. Liu et al. conducted a meta-analysis that showed comparable results regarding the effect of eTRE versus lTRE on lipid metabolism [41]. However, the depth of all these analyses is limited to the usual clinical parameters such as cholesterol, LDL and HDL. Implementing lipidomic analysis in the chrononutritional research provides new findings on the metabolic regulation by the eating timing.

Generally, a large part of the plasma lipidome demonstrates circadian rhythmicity in constant routine studies, demonstrating an essential role of the endogenous circadian clock in lipid homeostasis [42-44]. Indeed, the molecular clock machinery induces circadian rhythms of essential lipid metabolism enzymes via clock-controlled transcription factors such as PPARs, PGC-1alpha, and SREBPs [44-47]. Remarkably, circadian lipidome organization is altered both in circulation and in the adipose tissue in subjects with type 2 diabetes suggesting a high relevance of lipid rhythm dysregulation to the diabetes pathogenesis [48]. Further, we previously found that the plasma lipidome responds differently to the same meal depending on the time of day, with one-third of all lipids showing higher postprandial changes after the morning meal compared to the afternoon meal [26]. This aligns with our finding that eTRE has more pronounced effects on the plasma lipidome compared to lTRE.

Results of our study are also in some degree comparable with data of Madkur et al. [25] which is the only published study to date investigating the impact of any form of intermittent fasting, in their case Ramadan fasting, on the plasma lipidome by using lipidomic analysis. Even though Ramadan fasting and TRE interventions, studied in our trial, differ in their timing of the eating window, the two studies are still very comparable as different forms of intermittent fasting. The study reported similar lipid pattern changes especially for the sphingomyelins after 29-30 days of the Ramadan fasting, but in contrast to our data, the ceramide class did not change.

Our finding on the ceramide reduction by eTRE might be clinically relevant, because elevated ceramides are associated with metabolic disfunction. Numerous studies have described increased ceramide levels in context of type 2 diabetes and cardiovascular diseases [49-53] as well as obesity and weight gain [54, 55]. Ceramides might be even used as a biomarkers for cardiovascular diseases in daily clinical practice [49, 56-59], so that some clinics have already started using ceramide-based scores to identify patients at risk for cardiometabolic diseases [60]. In the context of published studies, the observed reduction in both the total ceramide class and the single ceramide species suggests that eTRE potentially induced greater cardiometabolic benefits than ITRE. Our data obtained in the lipid enrichment analysis of the plasma lipidome align with these findings. In this analysis, we revealed a number of lipid species belonging to the glycerophospholipid pathway, which was found to be associated with cardiovascular risk and coronary artery disease progression [61, 62].

For estimated lipid metabolism enzyme activities, similar tendencies regarding the effects of eTRE and ITRE were observed. Specifically, in the context of diabetes, a reduction in D5D activity and an elevation in D6D activity are often described as associated factors [63-67]. Beyond diabetes, these changes in desaturase activities are associated with the metabolic syndrome, elevated fasting plasma triglycerides, C-reactive protein, HOMA-IR, and HbA1c [66, 68-71]. In this context, the FA-derived D5D index increase in eTRE and ITRE and D6D index reduction in ITRE observed in our study confirm beneficial metabolic effects of TRE. However, the D9D index, which was increased by eTRE, was described to be positively associated with BMI and triglyceride levels [65]. Therefore, effects of TRE timing on the lipid metabolism enzyme activities need careful interpretation, especially considering that the index calculation in our work was based on FAs within complex lipids and not on the free FAs as in previously published studies.

The results of the expression analysis of the same genes in the SAT partly disagree with the enzyme indices findings in plasma. For example, we found a higher expression of the desaturases FADS1/D5D and SCD1/D9D after the lTRE intervention compared to the eTRE. In plasma we couldn't see any difference regarding the corresponding enzyme indices. In turn, higher ELOVL6 expression levels in SAT after lTRE did not align with ELOVL6 index changes in plasma.

Following observed changes in plasma ceramide and phosphatidylcholines, we also quantified the mRNA expression of key enzymes involved in their metabolism. In particular, CHPT1 and SPTLC2, the essential genes of ceramide and phosphatidylcholine metabolism, respectively, have previously been characterized as circadian enzymes in human muscles [72]. Based on lipidomic data and on the *zeitgeber* role of food intake for central peripheral circadian clocks as shown in animal [73] and few human trials [74, 75], we expected to observe expression differences between eTRE and lTRE. However, contrary to our expectations, no significant differences in the expression of these and other analyzed genes were found between samples collected after eTRE and lTRE. This and the abovementioned discrepancy in the data on circulating and adipose tissue expression levels can be attributed to the fact that circulating lipids are mostly synthesized in the liver; thus, their levels may not accurately reflect the ongoing metabolism in SAT. Further, the measurement of the mRNA levels does not assess the translational and post-translational regulation of corresponding enzymes. Similarly, no difference between eTRE and lTRE in the expression of genes involved in fatty acid synthesis (FASN, ACC1 and ACSL1) also showed circadian rhythmicity in previous studies [37, 38], were found.

Using the novel metaKEGG tool [Gaugel J., Haacke N., Lazaratos M., submitted, https://metakegg.apps.dzd-ev.org, https://github.com/dife-bioinformatics/metaKEGG] combining the lipid pathway enrichment analysis and transcriptome data from SAT allowed to reveal three genes, PLB1, PLA2G6, and PLAG4B, involved in the effects of TRE timing on lipid homeostasis. They contribute to the glycerophospholipid pathway and code phospholipase enzymes and cleave acyl chains from the *sn*-1 and *sn*-2 positions of a phospholipid. Three identified genes were regulated differently by the TRE timing. PLB1 and PLA2G6 were downregulated, while PLAG4B were upregulated after the eTRE intervention compared to the lTRE. Whereas PLA2G6 is a proinflammatory mediator required for monocyte chemotaxis and potentially contributory to both atherosclerosis and diabetes [76],

the link between both PLAG4B & PLB1 and obesity, diabetes or cardiovascular diseases is currently unknown. Nevertheless, our findings provide a new insight on the role of phospholipases in TRE effects.

Some strengths and limitations have to be discussed when interpreting the results of this work. As mentioned above, the main strength is an absolute novelty of the data on TRE effects on the plasma lipidome. Secondly, effects of predefined early vs late eating windows on the plasma lipidome were investigated, which was never studied before. Many previous studies used a self-defined eating window, which did not allow to assess effects of different timed eating windows [4, 10, 12, 18, 40]. The third important strength is the crossover design of the study allowing to exclude the impact of the interindividual factors. The next strength, and one of most important strengths of this study, is an isocaloric intervention accompanied by the unchanged food composition which was achieved by an intensive nutritional counselling and careful control of food intake described in detail previously [27]. Nevertheless, in the eTRE, minimal caloric reduction could not be completely avoided, although it was lower than in comparable TRE studies [6, 7, 10, 77, 78]. The importance of this factor should not be overlooked, especially in context of more remarkable lipid changes after the eTRE intervention compared to the lTRE. Finally, the combination of the plasma lipidome and adipose tissue analysis represents an important strength of this work providing an insight into the role of the adipose tissue in lipid homeostasis regulation by TRE intervention.

One study limitation is that it was conducted only in mostly postmenopausal women, which might impede the generalizability of the study findings for the common population. Secondly, as already mentioned above, the enzyme activity levels in circulation were assessed not directly but estimated based on the fatty acid levels within complex lipids and need to be interpreted with caution. The relatively small sample size can also be a limiting factor but should not be overinterpreted due to the crossover study design. Nevertheless, future research in other population groups and larger cohorts needs to confirm the results of our study.

In summary, our study provides new insights into the effects of TRE on lipid metabolism. Our study highlighted marked differences between the effect of eTRE and lTRE on lipid metabolism both in plasma lipidome and adipose tissue. These novel findings open the

avenue for future research elucidating molecular mechanisms of meal timing-induced metabolic changes.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS
  - Study design and patient characteristics
- METHOD DETAILS
  - Blood plasma and adipose tissue collection
  - Lipidomic analyses of plasma samples
  - Gene expression analyses of adipose tissue
- QUANTIFICATION AND STATISTICAL ANALYSIS
  - RNAseq data processing
  - Lipid pathway enrichment analysis
  - Overlapping RNAseq and lipid pathway enrichment analysis
- ADDITIONAL RESOURCES

Acknowledgments

We acknowledge all study participants for their cooperation. We gratefully thank Juliane Roeder, Melanie Hannemann, and Lothar Napieralski for their work with study subjects; Katja Treu and Christiana Gerbracht for the help in the preparation of nutritional counselling; Marion Urbich and Nadine Huckauf for excellent technical assistance in the sample analysis. We also thank all students who contributed to the preparation and conduction of the clinical trial.

The study was supported by the German Research Foundation (DFG RA 3340/3-1, project number 434112826 and DFG RA 3340/4-1, project number 530918029 to OP-R), by the German Diabetic Association (Allgemeine Projektförderung der DDG 2020 and 2023 to OP-R); and by the European Association for Study of Diabetes 2020 (Morgagni Prize 2020 to OP-R). Funders were not involved in preparation of study design and implementation of the study; data collection, management, data analyzation, and interpretation; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author Contribution

M.J.G. performed lipidomics experiments; M.J.G. and S.K. performed the data analyses; A.M., A.F.H.P., A.K., and O. P-R conceptualized the clinical trial; B.P., J.S., and B.S. conducted the trial and provided the samples; C.K. and K.Si contributed to the lipidomics conceptualization; M.L. and R.S. conducted RNAseq data processing and lipid pathway enrichment analysis; K.S. drafted the manuscript; O.P-R. edited the manuscript; O.P-R. have unrestricted access to all data; all authors agreed to submit the manuscript, read and approved the final draft, and take full responsibility of its content, including the accuracy of the data and the fidelity of the trial to the registered protocol and its statistical analysis.

Declaration of Interest

Kai Simons and Christian Klose are shareholders of Lipotype GmbH. Mathias J. Gerl and Markus Damm are employees of Lipotype GmbH. Other authors declare no competing interests.

Inclusion and diversity

While citing references scientifically relevant for this work, we worked to promote gender balance in our reference list.

Supplemental information

Document S1. Tables S1-S12

Figure S1.

References

1. Barnosky, A.R., et al., *Intermittent fasting vs daily calorie restriction for type 2 diabetes prevention: a review of human findings.* Transl Res, 2014. **164**(4): p. 302-11.
2. Gill, S. and S. Panda, *A Smartphone App Reveals Erratic Diurnal Eating Patterns in Humans that Can Be Modulated for Health Benefits.* Cell Metab, 2015. **22**(5): p. 789-98.
3. Chow, L.S., et al., *Time-Restricted Eating Effects on Body Composition and Metabolic Measures in Humans who are Overweight: A Feasibility Study.* Obesity (Silver Spring), 2020. **28**(5): p. 860-869.
4. Cai, H., et al., *Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial.* BMC Gastroenterol, 2019. **19**(1): p. 219.
5. Lowe, D.A., et al., *Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity: The TREAT Randomized Clinical Trial.* JAMA Intern Med, 2020. **180**(11): p. 1491-1499.
6. Gabel, K., et al., *Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: A pilot study.* Nutr Healthy Aging, 2018. **4**(4): p. 345-353.
7. Cienfuegos, S., et al., *Effects of 4- and 6-h Time-Restricted Feeding on Weight and Cardiometabolic Health: A Randomized Controlled Trial in Adults with Obesity.* Cell Metab, 2020. **32**(3): p. 366-378.e3.
8. Moro, T., et al., *Effects of eight weeks of time-restricted feeding (16/8) on basal metabolism, maximal strength, body composition, inflammation, and cardiovascular risk factors in resistance-trained males.* J Transl Med, 2016. **14**(1): p. 290.
9. Kesztyüs, D., et al., *Adherence to Time-Restricted Feeding and Impact on Abdominal Obesity in Primary Care Patients: Results of a Pilot Study in a Pre-Post Design.* Nutrients, 2019. **11**(12).
10. Wilkinson, M.J., et al., *Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome.* Cell Metab, 2020. **31**(1): p. 92-104.e5.
11. Jones, R., et al., *Two weeks of early time-restricted feeding (eTRF) improves skeletal muscle insulin and anabolic sensitivity in healthy men.* Am J Clin Nutr, 2020. **112**(4): p. 1015-1028.
12. McAllister, M.J., et al., *Time-restricted feeding improves markers of cardiometabolic health in physically active college-age men: a 4-week randomized pre-post pilot study.* Nutr Res, 2020. **75**: p. 32-43.
13. Tinsley, G.M., et al., *Time-restricted feeding in young men performing resistance training: A randomized controlled trial.* Eur J Sport Sci, 2017. **17**(2): p. 200-207.
14. Hutchison, A.T., et al., *Time-Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial.* Obesity (Silver Spring), 2019. **27**(5): p. 724-732.
15. Karras, S.N., et al., *Effects of orthodox religious fasting versus combined energy and time restricted eating on body weight, lipid concentrations and glycaemic profile.* Int J Food Sci Nutr, 2021. **72**(1): p. 82-92.
16. Li, C., et al., *Eight-hour time-restricted feeding improves endocrine and metabolic profiles in women with anovulatory polycystic ovary syndrome.* J Transl Med, 2021. **19**(1): p. 148.
17. Peeke, P.M., et al., *Effect of time restricted eating on body weight and fasting glucose in participants with obesity: results of a randomized, controlled, virtual clinical trial.* Nutr Diabetes, 2021. **11**(1): p. 6.
18. Phillips, N.E., et al., *The Effects of Time-Restricted Eating versus Standard Dietary Advice on Weight, Metabolic Health and the Consumption of Processed Food: A Pragmatic Randomised Controlled Trial in Community-Based Adults.* Nutrients, 2021. **13**(3).
19. Sutton, E.F., et al., *Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes.* Cell Metab, 2018. **27**(6): p. 1212-1221.e3.

20. Jamshed, H., et al., *Early Time-Restricted Feeding Improves 24-Hour Glucose Levels and Affects Markers of the Circadian Clock, Aging, and Autophagy in Humans.* Nutrients, 2019. **11**(6).

21. Goldberg, I.J., *Diabetic Dyslipidemia: Causes and Consequences.* The Journal of Clinical Endocrinology & Metabolism, 2001. **86**(3): p. 965-971.

22. Zeb, F., et al., *Effect of time-restricted feeding on metabolic risk and circadian rhythm associated with gut microbiome in healthy males.* Br J Nutr, 2020. **123**(11): p. 1216-1226.

23. Parr, E.B., et al., *Time-Restricted Eating as a Nutrition Strategy for Individuals with Type 2 Diabetes: A Feasibility Study.* Nutrients, 2020. **12**(11).

24. Surma, M.A., et al., *An automated shotgun lipidomics platform for high throughput, comprehensive, and quantitative analysis of blood plasma intact lipids.* Eur J Lipid Sci Technol, 2015. **117**(10): p. 1540-1549.

25. Madkour, M.I., et al., *Ramadan intermittent fasting is associated with ameliorated inflammatory markers and improved plasma sphingolipids/ceramides in subjects with obesity: lipidomics analysis.* Sci Rep, 2023. **13**(1): p. 17322.

26. Kessler, K., et al., *Shotgun Lipidomics Discovered Diurnal Regulation of Lipid Metabolism Linked to Insulin Sensitivity in Nondiabetic Men.* J Clin Endocrinol Metab, 2020. **105**(5).

27. Peters, B., et al., *Effects of Early vs. Late Time-Restricted Eating on Cardiometabolic Health, Inflammation, and Sleep in Overweight and Obese Women: A Study Protocol for the ChronoFast Trial.* Front Nutr, 2021. **8**: p. 765543.

28. Kjellqvist, S., et al., *Identification of Shared and Unique Serum Lipid Profiles in Diabetes Mellitus and Myocardial Infarction.* J Am Heart Assoc, 2016. **5**(12).

29. Gieger, C., et al., *Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.* PLoS Genet, 2008. **4**(11): p. e1000282.

30. Warensjö, E., M. Ohrvall, and B. Vessby, *Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women.* Nutr Metab Cardiovasc Dis, 2006. **16**(2): p. 128-36.

31. Vessby, B., et al., *Desaturation and elongation of Fatty acids and insulin action.* Ann N Y Acad Sci, 2002. **967**: p. 183-95.

32. Attie, A.D., et al., *Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia.* J Lipid Res, 2002. **43**(11): p. 1899-907.

33. Chen, M., et al., *Reprogramming of rhythmic liver metabolism by intestinal clock.* J Hepatol, 2023. **79**(3): p. 741-757.

34. Gréchez-Cassiau, A., et al., *The hepatic circadian clock regulates the choline kinase α gene through the BMAL1-REV-ERBα axis.* Chronobiol Int, 2015. **32**(6): p. 774-84.

35. Jang, Y.S., et al., *Temporal expression profiles of ceramide and ceramide-related genes in wild-type and mPer1/mPer2 double knockout mice.* Mol Biol Rep, 2012. **39**(4): p. 4215-21.

36. Zhou, X., et al., *Diurnal variations in polyunsaturated fatty acid contents and expression of genes involved in their de novo synthesis in pigs.* Biochem Biophys Res Commun, 2017. **483**(1): p. 430-434.

37. Chou, C.F., et al., *KSRP is critical in governing hepatic lipid metabolism through controlling Per2 expression.* J Lipid Res, 2015. **56**(2): p. 227-40.

38. Sun, S., et al., *Circadian rhythm-dependent induction of hepatic lipogenic gene expression in rats fed a high-sucrose diet.* J Biol Chem, 2019. **294**(42): p. 15206-15217.

39. Ravussin, E., et al., *Early Time-Restricted Feeding Reduces Appetite and Increases Fat Oxidation But Does Not Affect Energy Expenditure in Humans.* Obesity (Silver Spring), 2019. **27**(8): p. 1244-1254.

40. Martens, C.R., et al., *Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults.* Geroscience, 2020. **42**(2): p. 667-686.

41. Liu, J., P. Yi, and F. Liu, *The Effect of Early Time-Restricted Eating vs Later Time-Restricted Eating on Weight Loss and Metabolic Health.* J Clin Endocrinol Metab, 2023. **108**(7): p. 1824-1834.

42. Sinturel, F., W. Spaleniak, and C. Dibner, *Circadian rhythm of lipid metabolism.* Biochem Soc Trans, 2022. **50**(3): p. 1191-1204.

43. Petrenko, V., et al., *Lipid metabolism around the body clocks.* Prog Lipid Res, 2023. **91**: p. 101235.

44. Gooley, J.J. and E.C. Chua, *Diurnal regulation of lipid metabolism and applications of circadian lipidomics.* J Genet Genomics, 2014. **41**(5): p. 231-50.

45. Gooley, J.J., *Circadian regulation of lipid metabolism.* Proc Nutr Soc, 2016. **75**(4): p. 440-450.

46. Adamovich, Y., R. Aviram, and G. Asher, *The emerging roles of lipids in circadian control.* Biochim Biophys Acta, 2015. **1851**(8): p. 1017-25.

47. Gnocchi, D., et al., *Lipids around the Clock: Focus on Circadian Rhythms and Lipid Metabolism.* Biology (Basel), 2015. **4**(1): p. 104-32.

48. Sinturel, F., et al., *Circadian organization of lipid landscape is perturbed in type 2 diabetic patients.* Cell Rep Med, 2023. **4**(12): p. 101299.

49. Hilvo, M., et al., *Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients.* Eur Heart J, 2020. **41**(3): p. 371-380.

50. Fretts, A.M., et al., *Plasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study.* J Nutr, 2020. **150**(5): p. 1214-1222.

51. Peterson, L.R., et al., *Ceramide Remodeling and Risk of Cardiovascular Events and Mortality.* J Am Heart Assoc, 2018. **7**(10).

52. Lemaitre, R.N., et al., *Circulating Sphingolipids, Insulin, HOMA-IR, and HOMA-B: The Strong Heart Family Study.* Diabetes, 2018. **67**(8): p. 1663-1672.

53. Meeusen, J.W., et al., *Plasma Ceramides.* Arterioscler Thromb Vasc Biol, 2018. **38**(8): p. 1933-1939.

54. Wittenbecher, C., et al., *Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology.* Nat Commun, 2022. **13**(1): p. 936.

55. Hammerschmidt, P. and J.C. Brüning, *Contribution of specific ceramides to obesity-associated metabolic diseases.* Cell Mol Life Sci, 2022. **79**(8): p. 395.

56. Havulinna, A.S., et al., *Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort.* Arterioscler Thromb Vasc Biol, 2016. **36**(12): p. 2424-2430.

57. Tarasov, K., et al., *Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency.* J Clin Endocrinol Metab, 2014. **99**(1): p. E45-52.

58. Meikle, P.J., et al., *Plasma lipidomic analysis of stable and unstable coronary artery disease.* Arterioscler Thromb Vasc Biol, 2011. **31**(11): p. 2723-32.

59. Fernandez, C., et al., *Plasma lipid composition and risk of developing cardiovascular disease.* PLoS One, 2013. **8**(8): p. e71846.

60. Summers, S.A., *Could Ceramides Become the New Cholesterol?* Cell Metab, 2018. **27**(2): p. 276-280.

61. Iliou, A., et al., *Metabolic phenotyping and cardiovascular disease: an overview of evidence from epidemiological settings.* Heart, 2021. **107**(14): p. 1123-1129.

62. Chen, H., et al., *Comprehensive Metabolomics Identified the Prominent Role of Glycerophospholipid Metabolism in Coronary Artery Disease Progression.* Front Mol Biosci, 2021. **8**: p. 632950.

63. Prada, M., et al., *Plasma Lipidomic n-6 Polyunsaturated Fatty Acids and Type 2 Diabetes Risk in the EPIC-Potsdam Prospective Cohort Study.* Diabetes Care, 2023. **46**(4): p. 836-844.

64. Forouhi, N.G., et al., *Association of Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study.* PLoS Med, 2016. **13**(7): p. e1002094.

65. Wolters, M., et al., *Desaturase Activity Is Associated With Weight Status and Metabolic Risk Markers in Young Children.* J Clin Endocrinol Metab, 2015. **100**(10): p. 3760-9.

66. Jacobs, S., et al., *Evaluation of various biomarkers as potential mediators of the association between coffee consumption and incident type 2 diabetes in the EPIC-Potsdam Study.* Am J Clin Nutr, 2014. **100**(3): p. 891-900.

67. A, I.S.S., A.B. C, and J.S. A, *Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes.* Nutrients, 2019. **11**(9).

68. Do, H.J., et al., *Relationship between the estimates of desaturase activities and cardiometabolic phenotypes in Koreans.* J Clin Biochem Nutr, 2011. **49**(2): p. 131-5.

69. Kawashima, A., et al., *Plasma fatty acid composition, estimated desaturase activities, and intakes of energy and nutrient in Japanese men with abdominal obesity or metabolic syndrome.* J Nutr Sci Vitaminol (Tokyo), 2009. **55**(5): p. 400-6.

70. Domínguez-López, I., et al., *Relationship between estimated desaturase enzyme activity and metabolic syndrome in a longitudinal study.* Front Nutr, 2022. **9**: p. 991277.

71. Svendsen, K., et al., *Fatty acid profile and estimated desaturase activities in whole blood are associated with metabolic health.* Lipids Health Dis, 2020. **19**(1): p. 102.

72. Loizides-Mangold, U., et al., *Lipidomics reveals diurnal lipid oscillations in human skeletal muscle persisting in cellular myotubes cultured in vitro.* Proc Natl Acad Sci U S A, 2017. **114**(41): p. E8565-E8574.

73. Damiola, F., et al., *Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus.* Genes Dev, 2000. **14**(23): p. 2950-61.

74. Wehrens, S.M.T., et al., *Meal Timing Regulates the Human Circadian System.* Curr Biol, 2017. **27**(12): p. 1768-1775 e3.

75. Koppold-Liebscher, D.A., et al., *Effects of Daytime Dry Fasting on Hydration, Glucose Metabolism and Circadian Phase: A Prospective Exploratory Cohort Study in Baha'i Volunteers.* Front Nutr, 2021. **8**: p. 662310.

76. Hui, D.Y., *Phospholipase A(2) enzymes in metabolic and cardiovascular diseases.* Curr Opin Lipidol, 2012. **23**(3): p. 235-240.

77. Deng, Y., et al., *Effects of time-restricted eating on intrahepatic fat and metabolic health among patients with nonalcoholic fatty liver disease.* Obesity (Silver Spring), 2024.

78. Zhang, L.M., et al., *Randomized controlled trial for time-restricted eating in overweight and obese young adults.* iScience, 2022. **25**(9): p. 104870.

79. Matyash, V., et al., *Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics.* J Lipid Res, 2008. **49**(5): p. 1137-46.

80. Aimo, L., et al., *The SwissLipids knowledgebase for lipid biology.* Bioinformatics, 2015. **31**(17): p. 2860-6.

81. Liebisch, G., et al., *Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures.* J Lipid Res, 2020. **61**(12): p. 1539-1555.

82. Kanehisa, M. and S. Goto, *KEGG: kyoto encyclopedia of genes and genomes.* Nucleic Acids Res, 2000. **28**(1): p. 27-30.

83. Kanehisa, M., *Toward understanding the origin and evolution of cellular organisms.* Protein Sci, 2019. **28**(11): p. 1947-1951.

84. Kanehisa, M., et al., *KEGG: biological systems database as a model of the real world.* Nucleic Acids Res, 2025. **53**(D1): p. D672-d677.

85. Sherman, B.T., et al., *DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update).* Nucleic Acids Res, 2022. **50**(W1): p. W216-w221.

86. Huang da, W., B.T. Sherman, and R.A. Lempicki, *Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.* Nat Protoc, 2009. **4**(1): p. 44-57.

Table 1. Baseline characteristics of study participants.

Characteristics	
N (% Female)	31 (100%)
Age	58.4 ± 1.5
BMI (kg/m^2)	30.5 ± 0.5
Height (m)	1.65 ± 0.07
Weight (kg)	82.5 ± 8.4
Waist circumference (cm)	99 ± 9
Total cholesterol (mmol/L)	5.63 ± 0.92
HDL cholesterol (mmol/L)	1.46 (1.33-1.65)
LDL cholesterol (mmol/L)	3.47 ± 0.82
Triglycerides (mmol/L)	1.35 ± 0.62
Fasting glucose (mmol/L)	90 (87-96)
Systolic blood pressure (mmHg)	117 (110-135)
Diastolic blood pressure (mmHg)	75 (68-79)
Glycemic state (NGT:IFG/IGT)	18:13
Chronotype (early:normal:late)	18:11:2
HbA1c (%)	5.50 (5.22-5.70)

Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NGT, normal glucose tolerance; IFG/IGT, impaired fasting glucose/impaired glucose tolerance; HbA$_{1c}$, hemoglobin A$_{1c}$. For parameters with normal distribution mean and SD are reported, for parameters with non-normal distribution median and 25th IQR, and 75th IQR are reported.

Figures

Figure 1. Impact of eTRE and lTRE on lipid species profiles in plasma

(A)   Study design. Early TRE (eTRE), eating window between 8 a.m. and 4 p.m.; late TRE (lTRE), eating window between 1 pm and 9 pm; drops indicate the collection of blood samples for lipidomic analysis (red) and syringes indicate the SAT samples (black); V, visit.

(B)   Changes of the lipid species profile within the eTRE intervention.

(C)   Changes of lipid species profile within the lTRE intervention.

In (B) and (C): Volcano plot shows lipid species comparison after vs. before intervention. Logarithmic p-values of the Mann-Whitney-U Test without correction for multiple testing are displayed on the y-axis, fold changes of means are shown on the x-axis. Labels at the top indicate the direction of the fold change. Points with additional outlines (e.g. ☐■ vs. ■) show significant hits after Benjamini-Hochberg correction for multiple testing.

Figure 2. Lipid classes and enzyme activity indices in plasma and gene expression in adipose tissue

(A)   Lipid classes showed significant alterations within eTRE (orange) or lTRE (blue) intervention.

(B)   Activity indices of key lipid metabolism enzymes showed significant alterations within eTRE (orange) or lTRE (blue) intervention.

In (A) and (B): The boxes show the median and IQR, the whiskers show min to max. The data were tested using the Wilcoxon signed-rank test. The Benjamini-Hochberg method was used to control for FDR. Only lipid indices with significant differences after adjusting for multiple testing are shown. Significance levels are encoded as follows: *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

(C) Expression of key lipid enzymes in subcutaneous adipose tissue (SAT). Relative mRNA expression of the desaturases FADS1/D5D, FADS2/D6D, SCD1/D9D; elongases ELOVL5, ELOVL6; FA synthesis enzymes FASN, ACC1, ACSL1; PC and CER synthesis enzymes CHPT1, CEPT1, SPTLC2 and CERS6 in SAT samples collected after eTRE and lTRE intervention is shown. All data were normalized to the geometric mean of the housekeeper genes beta-glucuronidase (GUSB) and P0 of 60S ribosomal protein large subunit RPLP0 after quantification by qPCR. The boxes show the median and IQR, the whiskers show min to max. Significances are encoded as follows: *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$.

Figure 3. Selected areas of the glycerophospholipid pathway combining lipid and gene expression data.

(A) Upper zoomed area of the glycerophospholipid pathway.

(B) Lower zoomed area of the glycerophospholipid pathway.

In (A) and (B): Glycerophospholipid pathway (KEGG ID: *hsa00564*) was identified by the lipid pathway enrichment analysis of plasma lipidome, and its full map is presented in Figure S1. The output of the lipid pathway enrichment analysis was subjected to metaKEGG tool, and the KEGG compounds belonging to the enriched pathway were highlighted. Genes found in the SAT transcriptome dataset were directly mapped on the pathway and colored according to their $\log_2$(FC) translated to a color scale. In the color scale, red color means a positive $\log_2$(FC), i.e. the transcript was upregulated in ITRF compared to the eTRE, whereas green color means a negative $\log_2$(FC). This allowed to identify three genes coding phospholipase enzymes PLB1, PLA2G6, and PLAG4B, which were regulated differently after eTRE and lTRE interventions.

STAR Methods

Key resources table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Biological samples		
Plasma and adipose tissue samples from women with overweight or obesity (the ChronoFast cohort)	German Institute of Human Nutrition Potsdam-Rebruecke [27]	Clinicaltrial.gov Identifier: NCT04351672
Chemicals, peptides, and recombinant proteins		
RNase-free Water	MP Biomedicals llc.	Cat.Nr: 7732-18-5
High-Capacity cDNA Reverse Transcription Kit	ThermoFisher Scientific / Applied Biosystems™	Cat.Nr: 4368814
RNase-Inhibitor	ThermoFisher Scientific / Applied Biosystems™	Cat.Nr: N8080119
384-Well Multiply®-PCR Plate	ThermoFisher Scientific / Applied Biosystems™	Cat.Nr: AB1384
*Power*SYBR® Green PCR Master Mix	ThermoFisher Scientific / Applied Biosystems™	Cat.Nr: 4367659
qRCR Primers	Invitrogen	N/A
Deposited data		
Raw RNAseq data for adipose tissue samples		N/A
Software and algorithms		
MinimPy	Open source software	https://sourceforge.net/projects/minimpy/
SPSS Statistics 25.0	IBM	https://www.ibm.com/de-de/products/spss-statistics
GraphPad Prism Version 5.0	GraphPad	https://www.graphpad.com/

Bodygram^{TM}	AKERN	https://www.akern.com/en/products-and-solutions/data-analysis-software/bodygram-software/
Fddb App and Food Database	Food Database GmbH	https://fddb.info/
ActiLife Version 6.13.4	ActiGraph	https://theactigraph.com/
QuantStudio^{TM} Real-Time PCR Software	ThermoFisher Scientific	https://www.thermofisher.com/de/de/home/global/forms/life-science/quantstudio-6-7-flex-software.html
FastQC v0.12.1	Open source http://www.bioinformatics.babraham.ac.uk/projects/fastqc/	RRID:SCR_014583
STAR v2.7.11a	Open source https://github.com/alexdobin/STAR	RRID:SCR_004463
STRINGTIE v2.2.1	Open source https://ccb.jhu.edu/software/stringtie/	RRID:SCR_016323
DESeq2 v1.34.0	Open source https://bioconductor.org/packages/release/bioc/html/DESeq2.html	RRID:SCR_015687
Python v3.10.9	Open source https://www.python.org/	RRID:SCR_008394
R v4.1.2	Open source https://www.r-project.org/	RRID:SCR_001905

| LIPEA | Biomedical Cybernetics Group https://hyperlipea.org/ | N/A |

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Olga Ramich (olga.ramich@dife.de).

Materials availability

This study did not generate new unique reagents.

Data and code availability

- Lipidomics data supporting the findings of this study are included within the Article and Supplemental Materials. Additionally, this paper analyzes publicly available RNA-seq data. The accession number for this dataset is listed in the key resources table.

- This paper does not report original code.

- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Study design & participant characteristics

Thirty-one overweight or obese women have completed the randomized 10-weeks crossover clinical trial. Details of the participant recruitment, clinical characteristics of the study participants, dietary interventions, and adherence assessment were recently published [27]. Inclusion and exclusion criteria are described in **Table S1**. In brief, inclusion criteria were female sex, age between 18 and 70 years, and BMI between 25 and 35 kg/m^2. Exclusion criteria were diabetes type 1 or type 2, shift work and travel across more than one time zone one moths before or during the study. The study protocol and informed consent form were approved by the Medical Ethics Committee of the University of Potsdam (EA No. 8/2019) and comply with the Declaration of Helsinki of 1975 as revised in 2013. All participants

provided written informed consent prior to the study participation. The study was registered at clinicaltrials.gov on 17.04.2020 (Identifier: NCT04351672).

For a detailed description of the study protocol, refer to [27]. In brief, after a 2-4-week baseline phase, two isocaloric 2-week interventions – (i) eTRE and (ii) lTRE - were conducted, separated by a 2-week washout phase (**Figure 1A**). During the baseline phase, the participants consumed their usual food quality and quantity at their usual mealtime. In the eTRE intervention, participants were asked to consume the same kind and amount of food as during the baseline phase but to reduce their eating window to 8 h per day for a daytime from 8 am to 4 pm, while in the lTRE intervention, the 8-hour eating window shifted to 1 pm to 9 pm. Between the two interventions, participants returned to their usual eating times. Throughout the 8-10 weeks of the study, participants were asked to maintain their usual lifestyle habits in terms of physical activity and sleep. Eating behavior (timing, kind and amount of food) was monitored using digital or paper-based food records, while physical activity and sleep-wake rhythms were controlled by the actigraphy (ActiGraph wGT3X-BT, ActiGraph, Netherlands) and sleep logs, respectively, for 14 consecutive days of the baseline phase and during both TRE interventions. Energy intake, macronutrient composition, and eating times were assessed using the FDDB food database (Fddb Internetportale GmbH, https://fddb.info/) as described [27]. All days at which the subjects followed the required TRE eating time frame with maximally ± 30 minutes deviation were considered as compliant. As a measure of physical activity, the metabolic equivalent of task (MET) was analyzed using an ActiLife software version 6.13.4 (ActiGraph, Netherlands).

Before and after each intervention, metabolic examination of participants was conducted after an overnight fast using anthropometric measurements, 75 g-oral glucose tolerance test (OGTT), and blood sample collection as described [27]. Blood samples were collected in serum monovettes for blood glucose, HbA1c, and total lipid measurements. Participants' chronotypes were determined using the Munich Chronotype Questionnaire (MCTQ) and the Horne-Östberg Morningness-Eveningness Questionnaire (MEQ) as described [27].

METHOD DETAILS

Blood plasma and adipose tissue collection

For lipidomics analysis, fasting blood samples were drawn at 9.30 a.m. before and after eTRE and lTRE interventions (visits 1-4 at **Figure 1A**) using EDTA monovettes (Sarstedt, Germany).

Blood plasma was frozen immediately after the centrifugation and stored at -80°C until analysis. Subcutaneous adipose tissue (SAT) was collected periumbilically at 9.30 a.m. after both interventions (visits 2 and 4). Before each biopsy, a skin area of approximately 2×2 cm was treated with lidocaine for anesthesia. A 3-mm incision was then made in the skin using a fine needle (diameter 2.1 mm) connected to a vacuum syringe containing sterile NaCl solution. The resulting negative pressure allowed small pieces of tissue to be removed. These were immediately cleaned in a NaCl solution, frozen in aliquots a 0.4 g in liquid nitrogen and stored at -80 °C until analysis.

Lipidomics analyses of plasma samples

Lipidomic measurements in blood plasma were performed using mass spectrometry-based shotgun lipidomic analysis at Lipotype GmbH (Dresden, Germany) as described [24]. For lipid extraction, an equivalent of 1 µl of undiluted plasma was used, and plasma lipids were extracted with methyl tert-butyl ether/methanol (7:2, V:V) [79]. Samples were analyzed by direct infusion in a QExactive mass spectrometer (Thermo Scientific, Bremen, Germany) equipped with a TriVersa NanoMate ion source (Advion Biosciences, Ithaca, New York, United States of America). Samples were analyzed in both positive and negative ion modes with a resolution of $R_{m/z = 200} = 280,000$ for MS and $_{Rm/z = 200} = 17,500$ for MSMS experiments in a single acquisition. Lipids were identified and quantified employing the proprietary LipotypeXplorer software. Lipid intensities were normalized to lipid class-specific internal standards, and data were reported as molar amounts. Analytical quality was evaluated by incorporating reference and blank samples. Data were corrected for batch effects and drift based on reference samples. Lipid species present in less than 70% of all samples were excluded.

Lipid species were annotated based on their molecular composition, indicating the sum of carbon atoms in the hydrocarbon moiety, the sum of double bonds, and the sum of hydroxyl groups. For instance, PI 34:1;0 denotes phosphatidylinositol with a total length of its fatty acids equal to 34 carbon atoms, total number of double bonds in its fatty acids equal to 1, and 0 hydroxylations. The annotation of lipid subspecies provides additional information on the exact identity of their acyl moieties and their sn-position (if available). For example, PI 18:1;0_16:0;0 denotes phosphatidylinositol with octadecenoic (18:1;0) and hexadecanoic (16:0;0) fatty acids, for which the exact position (sn-1 or sn-2) in relation to the glycerol backbone cannot be discriminated (underscore "_" separating the acyl chains). In contrast,

PC O-18:1;0/16:0;0 denotes an ether-phosphatidylcholine, where an alkyl chain with 18 carbon atoms and 1 double bond (O-18:1;0) is ether-bound to sn-1 position of the glycerol, and a hexadecanoic acid (16:0;0) is connected via an ester bond to the sn-2 position of the glycerol (slash "/" separating the chains signifies that the sn-position on the glycerol can be resolved). Lipid identifiers from the SwissLipids database [80] and the shorthand notation for MS-derived lipid structures[81] are provided. All lipid species and lipids classes identified by this method are shown in **Table S3**.

Assessment of lipid enzyme activity indices

Based on the level of specific lipids, the overall amount of fatty acids (FA) within complex lipid was assessed. Enzyme activity indices were calculated as ratio between two FAs and used as surrogate activity markers of corresponding enzyme responsible for the conversion from one FA to another. Following indices were assessed in this study: delta-5 desaturase (D5D/FADS1), delta-6 desaturase (D6D/FADS2) [28], elongation of very long chain fatty acids protein 5 (ELOVL5) [28], elongation of very long chain fatty acids protein 6 (ELOVL6) [28], stearoyl-CoA desaturase 1/delta-9 desaturase - C16 (SCD1/D9D (C16)), stearoyl-CoA desaturase 1/delta-9 desaturase - C18 (SCD1/D9D (C18)), stearoyl-CoA desaturase 1/delta-9 desaturase - C18+16 (SCD1/D9D (C18+16)) [30-32] (**Table S4**).

Gene expression analyses of adipose tissue

Total RNA was isolated from subcutaneous adipose tissue (SAT) samples using the RNeasy Lipid Tissue Mini Kit (Qiagen, Germany). RNA concentration was determined utilizing an ND-1000 spectrophotometer (Nanodrop, PeqLab), and the RNA quality was determined by the Bioanalyser (Agilent). Extracted RNA samples all had RIN values of ≥ 8. For the qPCR analysis, single-stranded cDNA was generated using the QuantiTect Reverse Transcription Kit (Qiagen, Germany). Quantitative PCR (qPCR) was conducted on the ViiA 7 sequence detection system using Power SYBR Green PCR Master Mix (Applied Biosystems, USA) and specific primers (**Table S5**). Gene expression was evaluated using the standard curve method and normalized to the geometric mean of housekeeper genes beta-glucuronidase (GUSB) and P0 protein of 60S ribosomal protein large subunit (RPLPO). Whole-genome transcriptome analysis was performed by RNA-sequencing by BGI Genomics (BGI-Copenhagen, Denmark) using BGISEQ platform with 100 bp paired-end reads.

QUANTIFICATION AND STATISTICAL ANALYSES

Statistical analyses were performed with SPSS v.25 (SPSS, Chicago, IL) and R version 4.2.3 (2023-03-15) using tidyverse packages (version 2.0.0). $P < 0.05$ was considered statistically significant in all analyses. Comparison between two groups was conducted by the paired Wilcoxon signed-rank test or by the unpaired the Mann–Whitney U test. For the multiple testing correction, the Benjamini–Hochberg (BH) method was used. All data are presented as means ± standard deviation (SD).

RNAseq data processing

RNA-seq data were delivered by BGI in form of adapter and low-quality reads cleaned sequencing data. FastQC v0.12.1 was employed to assess quality of the samples. Reads were aligned to the reference genome (GRCh38.110/hg38) using STAR 2.7.11a, and fragments per kilobase per million (FPKM) values for transcripts were determined by STRINGTIE v2.2.1, both with default options for paired reads. Differential gene expression analysis was performed via the R-package DESeq2 (v1.34.0) pipeline. Transcripts with mean expression values > 1 FPKM, and $p < 0.05$ were considered statistically significant. RNAseq data processing was performed with R v4.1.2.

Lipid pathway enrichment combined with SAT transcriptome analysis

All the differentially abundant lipid species were subjected to lipid pathway enrichment analysis using online tool LIPEA (https://hyperlipea.org/). The lipid species belonging to the same lipid class were merged and KEGG pathway enrichment analysis [82-86] output included the lipid/compound ID mapping to the enriched pathways.

The output of the lipid pathway enrichment analysis was subjected to metaKEGG tool [Gaugel J., Haacke N., Lazaratos M., submitted, https://metakegg.apps.dzd-ev.org, https://github.com/dife-bioinformatics/metaKEGG] to visualize lipidomic and transcriptomic layers. For this application, we used the analysis pipeline "Bulk RNAseq mapping" in order to directly map the KEGG pathway that emerged from the lipid pathway enrichment analysis, bypassing the need for a gene pathway enrichment analysis. The pathway "Glycerophospholipid metabolism" (KEGG ID: *hsa00564*) was queried, using $\log_2(FC)$ values from only significantly (1 FPKM & $p < 0.05$) differentially expressed genes of the comparison eTRF vs. lTRF. The internal KEGG compound IDs for lipid species identified in enriched pathways were provided as an additional input parameter for the metaKEGG visualization pipeline. Genes found in the SAT RNAseq dataset were directly mapped on the pathway,

colored according to their $\log_2$(FC) translated to a color scale, while KEGG compounds were assigned a single color to highlighted their presence in the pathway.

ADDITIONAL RESOURCES

The study was registered at clinicaltrials.gov (Identifier: NCT04351672).